Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
2026-02-23 08:30:00 ET
In my last article, "Novo Nordisk: Will Wegovy And Pipeline Spark Rally?" , I mostly discussed Novo Nordisk's (NONOF) ( NVO ) Q3 results and the efficacy of 20 mg amycretin and UBT251....
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk: Why Wegovy Growth Beats Wall Street ExpectationsNASDAQ: MDGL
MDGL Trading
-2.75% G/L:
$424.11 Last:
209,153 Volume:
$431.65 Open:



